| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Citigroup analyst Samantha Semenkow maintains Prime Medicine (NASDAQ:PRME) with a Neutral and lowers the price target from $...
Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $...
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...
Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $...